Phase I study of hV01, a recombinant human IL-21-expressing oncolytic vaccinia virus, as monotherapy in advanced solid tumors. Initial safety and efficacy results from a first-in-human, phase 1/2 ...

Outcomes of continuing neoadjuvant-intent immunotherapy for advanced, resectable cutaneous squamous cell carcinoma post-operatively. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...

Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet.

While IL2 LD is not currently licensed for MND/ALS treatment, the MIROCALS results suggest that IL2 LD should now be considered for development as a safe and well tolerated treatment for MND, adding ...

While IL2 LD is not currently licensed for MND/ALS treatment, the MIROCALS results suggest that IL2 LD should now be considered for development as a safe and well tolerated treatment for MND, adding ...

SAN CARLOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating ...

asDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden ...